23 completed, 1 recruiting, 1 terminated, 1 unknown. 27 Phase 1, 5 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 27 | Completed 23, Recruiting 1, Terminated 1, Unknown 1, Withdrawn 1 |
| Phase 2 | 5 | Completed 3, Recruiting 1, Withdrawn 1 |
Follow LV: new trials by email Literature Review of LV trials Research Report on LV
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Liposomal Irinotecan + Oxaliplatin + Bevacizumab Versus Liposomal Irinotecan + 5-FU/LV Irinotecan liposoma, oxaliplatin, bevacizumab - Advanced Pancreatic Cancer (Part 1) | Phase 1 / Phase 2 | Recruiting | Dai, Guanghai | 138 | 2024-06-23 | 2025-01-20 |
| Dose Escalation and Expansion Clinical Trial of Irinotecan Liposome Combined With Oxaliplatin and 5-FU/LV Plus Bevacizumab as First-line Treatment of Metastatic Colorectal Cancer Irinotecan Liposome, Oxaliplatin, 5-FU - Metastatic Colorectal Cancer | Phase 1 | Unknown | Shanghai Zhongshan Hospital | 78 | 2024-03-11 | 2024-03-19 |
| Biweekly SOLAR, as First-line C/T in Pts With Gastric, Pancreatic and Biliary Cancers Oxaliplatin, Albumin-Bound Paclitaxel /nab-Paclitaxel, S-1 - Gastric Cancer in Situ, Pancreatic Cancers | Phase 1 | Completed | National Health Research Institutes, Taiwan | 18 | 2018-06-26 | 2022-04-07 |
| Safety and Efficacy of SGN-LIV1A Plus Pembrolizumab for Patients With Locally-Advanced or Metastatic Triple-Negative Breast Cancer ladiratuzumab vedotin, Pembrolizumab - Triple Negative Breast Neoplasms | Phase 1 / Phase 2 | Completed | Seagen Inc. | 185 | 2018-02-27 | 2025-12-12 |
| Carfilzomib and Hyper-CVAD in Treating Patients With Newly Diagnosed Acute Lymphoblastic Leukemia or Lymphoma carfilzomib, cyclophosphamide, vincristine sulfate - Contiguous Stage II Adult Lymphoblastic Lymphoma, Noncontiguous Stage II Adult Lymphoblastic Lymphoma | Phase 1 | Completed | Mehrdad Abedi, MD | 10 | 2015-12-17 | 2022-03-10 |
| C-Met Inhibitor AMG 337, Oxaliplatin, Leucovorin Calcium, and Fluorouracil in Treating Patients With Advanced Stomach or Esophageal Cancer c-Met inhibitor AMG 337, placebo, oxaliplatin - Adenocarcinoma of the Esophagus, Adenocarcinoma of the Gastroesophageal Junction | Phase 1 / Phase 2 | Withdrawn | Eastern Cooperative Oncology Group | 2015-03-06 | 2023-05-25 | |
| Genetically Modified Neural Stem Cells, Flucytosine, and Leucovorin for Treating Patients With Recurrent High-Grade Gliomas E. coli CD-expressing genetically modified neural stem cells, flucytosine, leucovorin calcium - Adult Anaplastic Astrocytoma, Adult Anaplastic Oligodendroglioma | Phase 1 | Completed | City of Hope Medical Center | 16 | 2014-10-28 | 2026-11-03 |
| MEK Inhibitor MEK162 in Combination With Leucovorin Calcium, Fluorouracil, and Oxaliplatin in Treating Patients With Advanced Metastatic Colorectal Cancer MEK inhibitor MEK162, leucovorin calcium, fluorouracil - Recurrent Colon Cancer, Recurrent Rectal Cancer | Phase 1 | Completed | City of Hope Medical Center | 26 | 2014-07-16 | 2026-10-19 |
| A Safety Study of SGN-LIV1A in Breast Cancer Patients ladiratuzumab vedotin, Trastuzumab - HER2 Positive Breast Neoplasms, Hormone Receptor Positive Breast Neoplasms | Phase 1 | Completed | Seagen Inc. | 290 | 2013-10-22 | 2023-03-07 |
| CPI-613 and Combination Chemotherapy in Treating Patients With Metastatic Pancreatic Cancer 6,8-bis(benzylthio)octanoic acid, oxaliplatin, leucovorin calcium - Acinar Cell Adenocarcinoma of the Pancreas, Duct Cell Adenocarcinoma of the Pancreas | Phase 1 | Completed | Wake Forest University Health Sciences | 21 | 2013-04-01 | 2023-07-12 |
| FOLFIRINOX Plus PF-04136309 in Patients With Borderline Resectable and Locally Advanced Pancreatic Adenocarcinoma Oxaliplatin, Irinotecan, Leucovorin - Pancreatic Neoplasms | Phase 1 | Completed | Washington University School of Medicine | 44 | 2012-04-01 | 2016-09-19 |
| Genotype-guided Dosing of mFOLFIRINOX Chemotherapy in Patients With Previously Untreated Advanced Gastrointestinal Malignancies oxaliplatin, irinotecan hydrochloride, leucovorin calcium - Acinar Cell Adenocarcinoma of the Pancreas, Adenocarcinoma of the Gallbladder | Phase 1 | Completed | University of Chicago | 79 | 2012-03-26 | 2020-05-08 |
| Everolimus and Combination Chemotherapy in Treating Patients With Metastatic Stomach or Esophageal Cancer fluorouracil, leucovorin calcium, oxaliplatin - Adenocarcinoma of the Esophagus, Adenocarcinoma of the Gastroesophageal Junction | Phase 1 / Phase 2 | Completed | City of Hope Medical Center | 6 | 2012-02-01 | 2017-05-31 |
| Radiolabeled Monoclonal Antibody Therapy, Combination Chemotherapy, and Bevacizumab in Treating Patients With Metastatic Colorectal Cancer irinotecan hydrochloride, leucovorin calcium, fluorouracil - Recurrent Colon Cancer, Recurrent Rectal Cancer | Phase 1 | Completed | City of Hope Medical Center | 3 | 2011-08-30 | 2026-10-16 |
| Panobinostat and Fluorouracil Followed By Leucovorin Calcium in Treating Patients With Stage IV Colorectal Cancer Who Did Not Respond to Previous Fluorouracil-Based Chemotherapy panobinostat, fluorouracil, leucovorin calcium - Recurrent Colon Cancer, Recurrent Rectal Cancer | Phase 1 | Terminated | University of Southern California | 7 | 2010-10-01 | 2015-05-27 |
| Stereotactic Radiation, Nelfinavir Mesylate & Neoadjuvant Chemotherapy in Locally Advanced Pancreatic Cancer gemcitabine hydrochloride, leucovorin calcium, fluorouracil - Adenocarcinoma of the Pancreas, Stage III Pancreatic Cancer | Phase 1 | Completed | University of Nebraska | 46 | 2007-11-05 | 2023-10-10 |
| A Study of PEP02 in Combination With 5-fluorouracil (5-FU) and Leucovorin (LV) in Advanced Solid Tumors PEP02, 5-FU, LV - Solid Tumor | Phase 1 | Completed | PharmaEngine | 16 | 2006-01-01 | 2016-08-30 |
| Combination Chemotherapy in Treating Young Patients With Advanced Solid Tumors oxaliplatin, fluorouracil, leucovorin calcium - Childhood Central Nervous System Choriocarcinoma, Childhood Central Nervous System Embryonal Tumor | Phase 1 | Completed | National Cancer Institute (NCI) | 42 | 2005-09-01 | 2013-05-03 |
| Suberoylanilide Hydroxamic Acid, Fluorouracil, Leucovorin, and Oxaliplatin in Treating Patients With Progressive Metastatic or Unresectable Colorectal Cancer or Other Solid Tumors oxaliplatin, leucovorin calcium, vorinostat - Recurrent Colon Cancer, Recurrent Rectal Cancer | Phase 1 | Completed | National Cancer Institute (NCI) | 54 | 2005-07-01 | 2013-09-30 |
| Chemoimmunotherapy With Epratuzumab in Relapsed Acute Lymphoblastic Leukemia (ALL) L-asparaginase, doxorubicin hydrochloride, therapeutic hydrocortisone - Recurrent Childhood Acute Lymphoblastic Leukemia | Phase 1 / Phase 2 | Completed | Children's Oncology Group | 134 | 2005-02-01 | 2017-12-12 |
Showing 20 of 27. Sign in to see all of them.
Rectal Neoplasms (7) · Colonic Neoplasms (6) · Pancreatic Neoplasms (5) · Stomach Neoplasms (3) · Adenocarcinoma Of Esophagus (2) · Esophageal Neoplasms (2) · Precursor Cell Lymphoblastic Leukemia-Lymphoma (2) · Triple Negative Breast Neoplasms (2) · Astrocytoma (1) · Bile Duct Neoplasms (1) · Biliary Tract Neoplasms (1) · Brain Neoplasms (1) · Breast Neoplasms (1) · Colorectal Neoplasms (1) · Gallbladder Neoplasms (1)
National Cancer Institute (NCI) (9) · City of Hope Medical Center (4) · Seagen Inc. (2) · Children's Oncology Group (1) · Dai, Guanghai (1) · Eastern Cooperative Oncology Group (1) · Mehrdad Abedi, MD (1) · National Health Research Institutes, Taiwan (1) · PharmaEngine (1) · Shanghai Zhongshan Hospital (1) · University of Chicago (1) · University of Nebraska (1) · University of Southern California (1) · Wake Forest University Health Sciences (1) · Washington University School of Medicine (1)
United States (23) · China (2) · Australia (1) · Canada (1) · Germany (1) · Puerto Rico (1) · South Korea (1) · Spain (1) · Taiwan (1)
Heinz-Josef Lenz (2) · Marwan Fakih (2) · Zejing Wang, MD, PhD (2) · Andrea Wang-Gillam, M.D., PhD (1) · Brandon Croft, PharmD (1) · Caio Rocha Lima, MD (1) · Chi Lin (1) · Daniel Haller (1) · Elizabeth Raetz, MD (1) · Gary K. Schwartz (1) · Gary Schwartz (1) · George Wilding (1) · Hedy Kindler (1) · Jana Portnow (1) · Jeffrey Wong, MD (1)
PMID 27055731, PMID 27871319, PMID 28495639, PMID 30825970, PMID 37678921, PMID 38902994
U01CA069856 (2), 2017 (1), P30CA012197 (1), P30CA036727 (1), U01CA062491 (1), U01CA062505 (1), U01CA070095 (1), U10CA021115 (1), U10CA098543 (1), U10CA180820 (1)